T. Rowe Price Associates’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-35,210
| Closed | -$40K | – | 3080 |
|
|
2025
Q2 | $40K | Sell |
35,210
-7,654
| -18% | -$9.35K | ﹤0.01% | 3023 |
|
|
2025
Q1 | $50K | Sell |
42,864
-3,526,135
| -99% | -$6.56M | ﹤0.01% | 2934 |
|
|
2024
Q4 | $21.8M | Sell |
3,568,999
-445,260
| -11% | -$5.29M | ﹤0.01% | 976 |
|
|
2024
Q3 | $66.4M | Sell |
4,014,259
-60,832
| -1% | -$666K | 0.01% | 672 |
|
|
2024
Q2 | $28M | Buy |
4,075,091
+187,068
| +5% | +$1.6M | ﹤0.01% | 868 |
|
|
2024
Q1 | $37.5M | Buy |
3,888,023
+628,001
| +19% | +$7.28M | ﹤0.01% | 799 |
|
|
2023
Q4 | $27.1M | Buy |
3,260,022
+17,307
| +0.5% | +$100K | ﹤0.01% | 870 |
|
|
2023
Q3 | $27.1M | Buy |
3,242,715
+11,845
| +0.4% | +$100K | ﹤0.01% | 846 |
|
|
2023
Q2 | $29.8M | Buy |
3,230,870
+1,109,995
| +52% | +$12.4M | ﹤0.01% | 836 |
|
|
2023
Q1 | $29.1M | Sell |
2,120,875
-85,532
| -4% | -$1.77M | ﹤0.01% | 824 |
|
|
2022
Q4 | $37.5M | Sell |
2,206,407
-11,359
| -0.5% | -$227K | 0.01% | 738 |
|
|
2022
Q3 | $50.4M | Sell |
2,217,766
-405,107
| -15% | -$8.18M | 0.01% | 642 |
|
|
2022
Q2 | $47.3M | Buy |
2,622,873
+376,832
| +17% | +$6.72M | 0.01% | 893 |
|
|
2022
Q1 | $60M | Sell |
2,246,041
-125,234
| -5% | -$2.33M | 0.01% | 907 |
|
|
2021
Q4 | $69.5M | Buy |
2,371,275
+13,811
| +0.6% | +$686K | 0.01% | 886 |
|
|
2021
Q3 | $155M | Buy |
2,357,464
+371,393
| +19% | +$28.4M | 0.01% | 631 |
|
|
2021
Q2 | $165M | Buy |
1,986,071
+189,760
| +11% | +$14.1M | 0.02% | 621 |
|
|
2021
Q1 | $138M | Buy |
1,796,311
+467,527
| +35% | +$42.6M | 0.01% | 673 |
|
|
2020
Q4 | $117M | Buy |
1,328,784
+460,573
| +53% | +$32.4M | 0.01% | 675 |
|
|
2020
Q3 | $64.1M | Sell |
868,211
-39,017
| -4% | -$2.31M | 0.01% | 791 |
|
|
2020
Q2 | $66.2M | Buy |
907,228
+88,926
| +11% | +$5.4M | 0.01% | 758 |
|
|
2020
Q1 | $45.9M | Sell |
818,302
-99,219
| -11% | -$4.35M | 0.01% | 811 |
|
|
2019
Q4 | $35M | Buy |
917,521
+102,242
| +13% | +$2.57M | ﹤0.01% | 1021 |
|
|
2019
Q3 | $14.5M | Buy |
+815,279
| New | +$16.5M | ﹤0.01% | 1234 |
|
Other funds holding IGMS
T. Rowe Price Associates's IGMS Position: Q3 2025 in Review
T. Rowe Price Associates sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 35,210 shares — an estimated $40K sold.
T. Rowe Price Associates first reported a position in IGMS in Q3 2019 and held it in 24 quarters. The position peaked at $165M in Q2 2021. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- T. Rowe Price Associates reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 35,210 IGM Biosciences shares in Q3 2025, an estimated $40K.
- T. Rowe Price Associates first reported a position in IGM Biosciences in Q3 2019 and held it in 24 quarters.
- T. Rowe Price Associates's IGM Biosciences position peaked at $165M in Q2 2021.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.